12 Empirical evidence presented in Frank and Salkever 1997 and Berndt Cockburn

12 empirical evidence presented in frank and salkever

This preview shows page 49 - 51 out of 60 pages.

12Empirical evidence presented in Frank and Salkever [1997] and Berndt, Cockburn and Griliches [1996] is consistent with the Frank-Salkever segmented market hypothesis. Related econometric evidence from Berndt, Griliches and Rosett [1993] suggests that over the 1986-1991 time period, prices of older drugs increased more rapidly than those on newer products. 13The original Dorfman-Steiner formulation was in the context of static optimization. Extensions to dynamic optimization are presented in Schmalensee [1972]. Most of the intuition generalizes to the dynamic environment. For additional discussions, see Hurwitz and Caves [1988] and Leffler [1981]. 14See, for example, Berndt, Bui, Lucking-Reiley and Urban [1995,1997], Perloff and Suslow [1994], and King [2000]. 15Generic firms may, however, engage in other marketing efforts for which the benefits are more easily internalized. We understand that generic firms market very differently from brand firms. Instead of engaging in detailing and journal advertising, generic firms tend to have home office major account representatives for particular customers, such as drug store chains, staff model managed care organizations, and mass merchandisers such as WalMart. 16The transformation factors are: Tagamet (cimetidine), 800 mg/day; Zantac (ranitidine), 300 mg/day; Pepcid, 40 mg/day; Axid, 300 mg/day; Prilosec, 20 mg/day; Prevacid, 30 mg/day; and Propulsid, 40 mg/day. Since Propulsid never had FDA approval for active duodenal ulcer treatment, we use the recommended daily dosage for treatment of nocturnal GERD. 17IMS Health [1998]. 18For an initial and preliminary analysis, see Prevention Magazine[1999]. Also see Wilkes, Bell and Kravitz [2000]. 19See STATA Reference Manual [1999]. 20For July 1995 onward (when the deflators first became available), we construct this deflator as the arithmetic average of the Producer Price Index for "Advertising agencies, ad creation, billed separately", and "Advertising agencies, media placement, including ad creation not billed". For months prior to July 1995, we employ the Producer Price Index for All Finished Goods. 21See Information Resources Inc. [1997], Guadagni-Little [1983], and Bucklin-Gupta [1999]. The IRI website is .
Background image
RX-OTC SWITCHES AND AFTERLIFE FOLLOWING PATENT PROTECTION- PAGE 50 -22This follows procedures utilized by Ling [1999] and Berndt, Bui, Lucking-Reiley and Urban [1995,1997]. 23Recommended dosages vary by indication. For example, while the recommended dosage of Zantac for treating active duodenal ulcers, active gastric ulcers, and GERD is 300 mg per day (either 300 mg once daily or 150 mg twice daily), the recommended dosage for duodenal ulcer maintenance therapy is only 150 mg per day. 24For each of the four OTC H2s, the transformation of OTC to Rx involves using twice the maximum daily recommended OTC dosages. 25Ling [1999]. The seven brands are Tums, Mylanta, Gaviscon, Maalox, Alka Seltzer, Rolaids and Pepto Bismol.
Background image
Image of page 51

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture